These sample sizes decreased to 12,270 patients with MS, 19,523 patients with Crohn’s disease, 142,683 patients with psoriasis, and 35,920 participants with No AID when applying the previously mentioned definitions of the study cohorts to ensure that only patients were included with secured diagnosis and diagnosed between 2008 and 2014 and to ensure a follow-up of 5 years after diagnosis (see “Methods” section and Figure 1). This evidence concerns the gene AICDA and psoriasis.